소세포 폐암 환자에서 이리노테칸, 카보플라틴 주별 분할항암요법의 효과
Weekly irinotecan and carboplatin for patients with small cell lung cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Lung cancer is the most common cause of cancer-related death worldwide and in Korea, and small cell lung cancer (SCLC) is the most deadly tumor type in the different lung cancer histology. Chemotherapy is the main strategy of the treatment for SCLC, and etoposide and platinum regimen has been the only standard chemotherapy for about 30 years. To test feasibility of weekly divided dose irinotecan and carboplatin for Korean patients is the aim of this study. Methods: Patients with histologically or cytologically confirmed extensive stage SCLC were included. Patients with limited stage (LD), who could not tolerate concurrent chemoradiotherapy were also included. All the patients received irinotecan 60 mg/m2, carboplatin 2 area under the curve at day 1, 8, and 15 every 4 weeks. Study regimen was discontinued when the disease progressed or intolerable side effects occurred. No more than 6 cycles of chemotherapy were given. Results: Total 47 patients were enrolled, among them 9 patients were LD. Overall response rate was 74.5% (complete response, 14.9%; partial response, 59.6%). Side effects greater than grade 3 were neutropenia (25.5%), fatigue (12.8%), thrombocytopenia (8.5%), sepsis (4.3%), and pancytopenia (2.1%). There was no treatment related death. Conclusion: Weekly divided irinotecan and carboplatin regimen is effective, and safe as a first line therapy for both stage of SCLC. Large scaled, controlled study is feasible.
Abstract
Background: Lung cancer is the most common cause of cancer-related death worldwide and in Korea, and small cell lung cancer (SCLC) is the most deadly tumor type in the different lung cancer histology. Chemotherapy is the main strategy of the treatment for SCLC, and etoposide and platinum regimen has been the only standard chemotherapy for about 30 years. To test feasibility of weekly divided dose irinotecan and carboplatin for Korean patients is the aim of this study. Methods: Patients with histologically or cytologically confirmed extensive stage SCLC were included. Patients with limited stage (LD), who could not tolerate concurrent chemoradiotherapy were also included. All the patients received irinotecan 60 mg/m2, carboplatin 2 area under the curve at day 1, 8, and 15 every 4 weeks. Study regimen was discontinued when the disease progressed or intolerable side effects occurred. No more than 6 cycles of chemotherapy were given. Results: Total 47 patients were enrolled, among them 9 patients were LD. Overall response rate was 74.5% (complete response, 14.9%; partial response, 59.6%). Side effects greater than grade 3 were neutropenia (25.5%), fatigue (12.8%), thrombocytopenia (8.5%), sepsis (4.3%), and pancytopenia (2.1%). There was no treatment related death. Conclusion: Weekly divided irinotecan and carboplatin regimen is effective, and safe as a first line therapy for both stage of SCLC. Large scaled, controlled study is feasible.
참고문헌 (26)
- Ferlay J, "Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)
- "Statistic of mortality of all ages in Republic of Korea for both sexes" (2013)[URL]
- Kim YC, "National survey of lung cancer in Korea, 2005", J Lung Cancer, 6, pp.67~73 (2007)
- "National Comprehnsive Cancer Network. Small cell lung cancer (version 2.2014); NCCN clinical practice guidelines in oncology (NCCN guidelines)" (2013)[URL]
- Noda K, "Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer", N Engl J Med, 346, pp.85~91 (2002)
- Hanna N, "Randomized phase III trial comparing irinotecan", cisplatin with etoposide, J Clin Oncol, pp.2006, 24[DOI]
- Schmittel A, "A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer", Ann Oncol, 22, pp.1798~1804 (2011)
- Han JY, "Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin", J Clin Oncol, 24, pp.2237~2244 (2006)
- Kim HS, "Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer", Cancer Chemother Pharmacol, 71, pp.1591~1597 (2013)
- Oken MM, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol, 5, pp.649~655 (1982)
- "Lung cancer staging" (2010)[URL]
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- "National Institute of Health. Common terminology criteria for adverse events (CTCAE) version 4.0"[URL]
- Horn L, "Harrison’s principles of internal medicine", pp.737~753 (2012), McGraw-Hill
- Ettinger DS, "Goldman’s cecil medicine", pp.2012, Elsevier
- Evans WK, "VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer", Cancer, 53, pp.1461~1466 (1984)
- Porter LL 3rd, "Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung", Cancer Treat Rep, 69, pp.479~481 (1985)
- Mathijssen RH, "Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)", Clin Cancer Res, 7, pp.2182~2194 (2001)
- Ma MK, "Lessons learned from the irinotecan metabolic pathway", Curr Med Chem, 10, pp.41~49 (2003)
- Mathijssen RH, "Irinotecan pathway genotype analysis to predict pharmacokinetics", Clin Cancer Res, 9, pp.3246~3253 (2003)
- Lara PN Jr, "Phase III trial of irinotecan", cisplatin compared with etoposide, J Clin Oncol, pp.2009, 27[DOI]
- Pao W, "New driver mutations in non-small-cell lung cancer", Lancet Oncol, 12, pp.175~180 (2011)
- Ardizzoni A, "Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923", J Clin Oncol, 20, pp.3947~3955 (2002)
- Pujol JL, "Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocytemacrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study", J Clin Oncol, 15, pp.2082~2089 (1997)
- Hong WK, "Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group", J Clin Oncol, 7, pp.450~456 (1989)
- Pectasides D, "Bountouroglou N, Karvounis N, et al. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-celllung cancer: a phase II study", Eur J Cancer, 38, pp.1194~1200 (2002)